NEULASTIM

This brand name is authorized in Brazil, Ecuador, Hong Kong SAR China, Israel, New Zealand, Singapore, South Africa, Turkey.

Active ingredients

The drug NEULASTIM contains one active pharmaceutical ingredient (API):

1	Pegfilgrastim UNII 3A58010674 - PEGFILGRASTIM
	Pegfilgrastim is a sustained duration form of filgrastim due to decreased renal clearance. Pegfilgrastim and filgrastim have been shown to have identical modes of action, causing a marked increase in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytes and/or lymphocytes.
	Read more about Pegfilgrastim

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
NEULASTIM Solution for injection	MPI, Generic	Health Products Regulatory Authority (ZA)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L03AA13	Pegfilgrastim	L Antineoplastic and immunomodulating agents → L03 Immunostimulants → L03A Immunostimulants → L03AA Colony stimulating factors
Discover more medicines within L03AA13

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	544117060004007, 544120090005107
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	63-MBE-0716
HK	Department of Health Drug Office	54933
IL	מִשְׂרַד הַבְּרִיאוּת	4971
NZ	Medicines and Medical Devices Safety Authority	12080
SG	Health Sciences Authority	13200P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699862950145
ZA	Health Products Regulatory Authority	42/8.5/0598